Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Active Rheumatoid Arthritis
Interventions: Tranilast, Placebo; Drug
Lead sponsor: Nuon Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Mesa, Arizona • Paradise Valley, Arizona • La Jolla, California + 6 more

Conditions: Bacterial Vaginosis
Interventions: Lactobacillus crispatus CTV-05, Metronidazole, Placebo; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Chicago, Illinois + 1 more

Conditions: Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma, Pancreatic Delta Cell Carcinoma, Pancreatic G-cell Carcinoma, Recurrent Islet Cell Carcinoma
Interventions: temozolomide, pazopanib hydrochloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 5
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more

Conditions: Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions: Sacituzumab govitecan, Atezolizumab, Durvalumab; Drug
Lead sponsor: Bindu R Potugari; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Sanfilippo Syndrome (MPS III)
Interventions: rAAV9-CMV-hNAGLUop; Biological
Lead sponsor: NeuroGT; Industry
Eligibility: 6 Months and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Neoplasms, Breast Cancer
Interventions: Vinflunine, Trastuzumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 10
States / cities: Anniston, Alabama • Fort Myers, Florida • Jacksonville, Florida + 7 more

Conditions: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions: Cetuximab, Encorafenib, Nivolumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 282
States / cities: Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: GTI-2040, capecitabine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Sacramento, California

Conditions: COVID19, COVID-19, COVID
Interventions: Pacritinib, Placebo; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Orange, California • Jacksonville, Florida • Atlanta, Georgia + 16 more

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Interventions: belinostat, Paclitaxel, Carboplatin; Drug
Lead sponsor: Valerio Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 7
States / cities: Newport Beach, California • Orlando, Florida • Covington, Louisiana + 4 more

Conditions: Type II Diabetes Mellitus
Interventions: AZD1656; Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: San Diego, California • San Antonio, Texas

Conditions: Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Topotecan, Transabdominal Ultrasound, Vincristine, X-Ray Imaging; Procedure · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 178
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: MGL-3196, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 26
States / cities: Dothan, Alabama • Tucson, Arizona • Coronado, California + 23 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Iza-bren, Carboplatin, Cisplatin, Pemetrexed, Amivantamab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 661 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 28
States / cities: Irvine, California • Orange, California • Edwards, Colorado + 22 more

Conditions: Pancreatic Adenocarcinoma
Interventions: Intraperitoneal Gemcitabine; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pleural Mesothelioma, Malignant Pleural Mesothelioma
Interventions: Cisplatin, Sodium Thiosulfate, ALIMTA; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hepatitis B
Interventions: Adefovir Dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Atezolizumab; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years to 99 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 13
States / cities: Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 10 more

Conditions: Scar Prevention
Interventions: EXC 001, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Chicago, Illinois • St Louis, Missouri

Conditions: Breast Cancer
Interventions: Entinostat, Atezolizumab, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more

Conditions: Healthy Participants
Interventions: IVX-A12, Licensed RSV Vaccine; Biological
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Anaheim, California • Rolling Hills Estates, California • Hollywood, Florida + 2 more

Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Interventions: Avatrombopag, Matching Placebo; Drug
Lead sponsor: Hanny Al-Samkari, MD; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Boston, Massachusetts • Portland, Oregon + 1 more

Conditions: Glioblastoma Multiforme
Interventions: XL184; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 5 more

Conditions: Age-related Macular Degeneration
Interventions: Resveratrol, Quercetin, Curcumin (RQC), Curcumin; Drug
Lead sponsor: Paul A Knepper, MD PhD; Other
Eligibility: 50 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

LACTIN-V Study for Recurrent Bacterial Vaginosis

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma

Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate

PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients

Atezolizumab Immunotherapy in Patients With Advanced NSCLC

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

A Study of IVX-A12 in Adults Participants

Avatrombopag vs. Placebo for CIT in GI Malignancies

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

A Study to Evaluate the Safety and Efficacy of RQC for AMD